XML 14 R5.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Operating activities    
Net loss $ (3,052,737) $ 43,754
NeuroOne LLC    
Operating activities    
Net loss   (16,707)
Adjustments to reconcile net loss to net cash used in operating activities:    
Amortization   5,823
Stock-based compensation   0
Forgiveness of share subscription agreement for founders' shares   0
Non-cash interest on convertible promissory notes   0
Non-cash discount amortization on short-term promissory notes and convertible promissory notes   0
Non-cash note issuance costs attributed to warrant liability   0
Revaluation of premium debt conversion derivative   0
Revaluation of warrant liability   0
Change in assets and liabilities:    
Prepaid expenses and other assets   0
Accrued expenses   10,884
Net cash used in operating activities   0
Financing activities    
Proceeds from issuance of short-term promissory notes and convertible promissory notes   0
Proceeds from issuance of warrants   0
Repayment of short-term unsecured loan   0
Issuance costs related to short-term promissory notes and convertible promissory notes   0
Issuance costs related to warrants   0
Net cash provided by financing activities   0
Net decrease in cash   0
Cash at beginning of period   0
Cash at end of period   0
Supplemental non-cash investing and financing transactions:    
Bifurcation of premium conversion derivative related to convertible promissory notes   0
Accrued issuance costs attributed to short term promissory notes and convertible promissory notes   0
Accrued issuance costs attributed to warrant liability   0
Common stock issued in connection with purchase of intangible assets   $ 0
NeuroOne, Inc. [Member]    
Operating activities    
Net loss (3,433,068)  
Adjustments to reconcile net loss to net cash used in operating activities:    
Amortization 13,368  
Stock-based compensation 76,794  
Forgiveness of share subscription agreement for founders' shares 9,051  
Non-cash interest on convertible promissory notes 76,359  
Non-cash discount amortization on short-term promissory notes and convertible promissory notes 943,427  
Non-cash note issuance costs attributed to warrant liability 38,119  
Revaluation of premium debt conversion derivative 90,212  
Revaluation of warrant liability (12,707)  
Change in assets and liabilities:    
Prepaid expenses and other assets 46,677  
Accrued expenses 642,099  
Net cash used in operating activities (1,509,669)  
Financing activities    
Proceeds from issuance of short-term promissory notes and convertible promissory notes 675,705  
Proceeds from issuance of warrants 502,415  
Repayment of short-term unsecured loan (50,000)  
Issuance costs related to short-term promissory notes and convertible promissory notes (38,719)  
Issuance costs related to warrants (31,920)  
Net cash provided by financing activities 1,057,481  
Net decrease in cash (452,188)  
Cash at beginning of period 522,217  
Cash at end of period 70,029  
Supplemental non-cash investing and financing transactions:    
Bifurcation of premium conversion derivative related to convertible promissory notes 213,961  
Accrued issuance costs attributed to short term promissory notes and convertible promissory notes 42,811  
Accrued issuance costs attributed to warrant liability 38,119  
Common stock issued in connection with purchase of intangible assets $ 23,115